Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 1.025
1.
Int J Biol Sci ; 20(7): 2491-2506, 2024.
Article En | MEDLINE | ID: mdl-38725850

Colon inflammation is characterized by disturbances in the intestinal microbiota and inflammation. Melatonin (Mel) can improve colon inflammation. However, the underlying mechanism remains unclear. Recent studies suggest that m6A methylation modification may play an important role in inflammatory responses. This study aimed to explore the effects of melatonin and LPS-mediated m6A methylation on colon inflammation. Our study found that melatonin inhibits M1 macrophages, activates M2 macrophages, inhibit the secretion of pro-inflammatory factors, maintain colon homeostasis and improves colon inflammation through MTNR1B. In addition, the increased methylation level of m6A is associated with the occurrence of colon inflammation, and melatonin can also reduce the level of colon methylation to improve colon inflammation. Among them, the main methylated protein METTL3 can be inhibited by melatonin through MTNR1B. In a word, melatonin regulates m6A methylation by improving abnormal METTL3 protein level to reshape the microflora and activate macrophages to improve colon inflammation, mainly through MTNR1B.


Adenosine , Lipopolysaccharides , Macrophages , Melatonin , Melatonin/pharmacology , Melatonin/metabolism , Animals , Mice , Adenosine/metabolism , Adenosine/analogs & derivatives , Adenosine/pharmacology , Methylation/drug effects , Macrophages/metabolism , Macrophages/drug effects , Methyltransferases/metabolism , Methyltransferases/genetics , Inflammation/metabolism , Colon/metabolism , Colon/drug effects , Male , Mice, Inbred C57BL , Colitis/chemically induced , Colitis/metabolism , Receptor, Melatonin, MT2/metabolism , Receptor, Melatonin, MT2/genetics , RAW 264.7 Cells
2.
Cancer Biol Ther ; 25(1): 2349429, 2024 Dec 31.
Article En | MEDLINE | ID: mdl-38738555

Cervical cancer (CC) is a prevalent malignancy among women worldwide. This study was designed to investigate the role of METTL14 in sorafenib-induced ferroptosis in CC. METTL14 expression and m6A methylation were determined in CC tissues, followed by analyzes correlating these factors with clinical features. Subsequently, METTL14 was knocked down in CC cell lines, and the effects on cell proliferation, mitochondrial morphology and ferroptosis were assessed using CCK-8, microscopy, and markers associated with ferroptosis, respectively. The regulatory relationship between METTL14 and FTH1 was verified using qRT-PCR and luciferase reporter assays. The functional significance of this interaction was further investigated both in vitro and in vivo by co-transfecting cells with overexpression vectors or shRNAs targeting METTL14 and FTH1 after sorafenib treatment. METTL14 expression and m6A methylation were significantly reduced in CC tissues, and lower METTL14 expression levels were associated with a poorer CC patients' prognosis. Notably, METTL14 expression increased during sorafenib-induced ferroptosis, and METTL14 knockdown attenuated the ferroptotic response induced by sorafenib in CC cells. FTH1 was identified as a direct target of METTL14, with METTL14 overexpression leading to increased m6A methylation of FTH1 mRNA, resulting in reduced stability and expression of FTH1 in CC. Furthermore, FTH1 overexpression or treatment with LY294002 partially counteracted the promotion of sorafenib-induced ferroptosis by METTL14. In vivo xenograft experiments demonstrated that inhibiting METTL14 reduced the anticancer effects of sorafenib, whereas suppression of FTH1 significantly enhanced sorafenib-induced ferroptosis and increased its anticancer efficacy. METTL14 reduces FTH1 mRNA stability through m6A methylation, thereby enhancing sorafenib-induced ferroptosis, which contributes to suppressing CC progression via the PI3K/Akt signaling pathway.


Ferroptosis , Methyltransferases , RNA Stability , Sorafenib , Uterine Cervical Neoplasms , Humans , Sorafenib/pharmacology , Sorafenib/therapeutic use , Female , Ferroptosis/drug effects , Ferroptosis/genetics , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/genetics , Mice , Animals , Methyltransferases/metabolism , Methyltransferases/genetics , RNA Stability/drug effects , Mice, Nude , Gene Expression Regulation, Neoplastic/drug effects , Methylation/drug effects , Cell Line, Tumor , Cell Proliferation/drug effects , Xenograft Model Antitumor Assays , RNA, Messenger/genetics , RNA, Messenger/metabolism , Prognosis , Ferritins , Oxidoreductases
3.
Neuroscience ; 545: 1-15, 2024 May 03.
Article En | MEDLINE | ID: mdl-38447691

Sevoflurane (Sev) anesthesia is associated with cognitive deficits and neurotoxicity. This study explores the epigenetic mechanism of SET domain containing 1B (SETD1B) in Sev-induced cognitive impairment in neonatal mice. Neonatal mice (C57BL/6, n = 72) were exposed to 3% Sev for 2 h per day at P6, 7, and 8, and the control neonatal mice were only separated from the mother for 2 h. The mice were divided into groups of 12 individuals, with an equal number of male and female mice in each group. Mice were intraperitoneally injected with adenovirus-packaged SETD1B overexpression vector. Behavioral tests (Morris water maze, open field test, T-maze, novel object recognition, etc.) were performed at P30. Mouse hippocampal neuronal cells were cultured in vitro. SETD1B, C-X-C motif chemokine receptor 4 (CXCR4), NLR family pyrin domain containing 1 (NLRP1), Cleaved Caspase1, and GSDMD-N expressions in hippocampal tissues or cells were determined by quantitative real-time polymerase chain reaction and Western blot. SETD1B and histone H3 lysine 4 methylation (H3K4me1, H3K4me2, and H3K4me3) enrichment on the CXCR4 promoter was analyzed by ChIP. Sev insulted cognitive impairment and diminished SETD1B expression in mouse hippocampal tissues. SETD1B overexpression mitigated cognitive impairment, enhanced H3K4me3 levels in hippocampal tissues, and restrained hippocampal neuronal pyroptosis. SETD1B increased CXCR4 expression by elevating the H3K4me3 level on the CXCR4 promoter, thereby curbing NLRP1/Caspase1-mediated hippocampal neuronal pyroptosis. To conclude, SETD1B enhances CXCR4 expression by elevating the H3K4me3 level on the CXCR4 promoter, thereby suppressing NLRP1/Caspase1-triggered hippocampal neuronal pyroptosis and alleviating Sev-induced cognitive impairment in neonatal mice.


Anesthetics, Inhalation , Animals, Newborn , Cognitive Dysfunction , Epigenesis, Genetic , Hippocampus , Histone-Lysine N-Methyltransferase , Histones , Mice, Inbred C57BL , Sevoflurane , Animals , Sevoflurane/pharmacology , Sevoflurane/toxicity , Cognitive Dysfunction/metabolism , Cognitive Dysfunction/chemically induced , Cognitive Dysfunction/genetics , Histone-Lysine N-Methyltransferase/metabolism , Histone-Lysine N-Methyltransferase/genetics , Epigenesis, Genetic/drug effects , Mice , Hippocampus/metabolism , Hippocampus/drug effects , Anesthetics, Inhalation/toxicity , Histones/metabolism , Female , Male , Receptors, CXCR4/metabolism , Receptors, CXCR4/genetics , Neurons/metabolism , Neurons/drug effects , Methylation/drug effects
4.
Nat Cancer ; 5(4): 601-624, 2024 Apr.
Article En | MEDLINE | ID: mdl-38413714

Current anticancer therapies cannot eliminate all cancer cells, which hijack normal arginine methylation as a means to promote their maintenance via unknown mechanisms. Here we show that targeting protein arginine N-methyltransferase 9 (PRMT9), whose activities are elevated in blasts and leukemia stem cells (LSCs) from patients with acute myeloid leukemia (AML), eliminates disease via cancer-intrinsic mechanisms and cancer-extrinsic type I interferon (IFN)-associated immunity. PRMT9 ablation in AML cells decreased the arginine methylation of regulators of RNA translation and the DNA damage response, suppressing cell survival. Notably, PRMT9 inhibition promoted DNA damage and activated cyclic GMP-AMP synthase, which underlies the type I IFN response. Genetically activating cyclic GMP-AMP synthase in AML cells blocked leukemogenesis. We also report synergy of a PRMT9 inhibitor with anti-programmed cell death protein 1 in eradicating AML. Overall, we conclude that PRMT9 functions in survival and immune evasion of both LSCs and non-LSCs; targeting PRMT9 may represent a potential anticancer strategy.


Arginine , Leukemia, Myeloid, Acute , Neoplastic Stem Cells , Nucleotidyltransferases , Protein-Arginine N-Methyltransferases , Protein-Arginine N-Methyltransferases/metabolism , Humans , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/immunology , Neoplastic Stem Cells/metabolism , Leukemia, Myeloid, Acute/immunology , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/drug therapy , Nucleotidyltransferases/metabolism , Arginine/metabolism , Methylation/drug effects , Animals , Mice , Interferon Type I/metabolism , DNA Damage , Cell Line, Tumor , Cell Survival/drug effects
5.
J. coloproctol. (Rio J., Impr.) ; 43(2): 139-151, Apr.-June 2023. ilus
Article En | LILACS | ID: biblio-1514434

Pseudomyxoma peritonei (PMP) refers to a growth disorder characterized by glycoprotein neoplasm in the peritoneum, where mucin oversecretion occurs. The tumors of the appendix region are well associated with PMP; however, ovarian, colon, stomach, pancreas, and urachus tumors have also been linked to PMP. Other mucinous tumors in the pelvis, paracolic gutters, greater omentum, retrohepatic space, and Treitz ligament can be the reason for PMP. Despite being rare and having a slow growth rate, PMP can be lethal without treatment. It is treated with neoadjuvant chemotherapy with the option of cytoreductive surgery and intraperitoneal chemotherapy. In the current study, we hypothesize that there may be novel gentle ways to inhibit or eliminate the mucin. Dr. David Morris has used mucolytics - such as bromelain and N-acetyl cysteine to solubilize mucin. In the present review, we aimed to study the regulation of mucin expression by promoter methylation, and drugs that can inhibit mucin, such as boldine, amiloride, naltrexone, dexamethasone, and retinoid acid receptors antagonist. This review also explored some possible pathways, such as inhibition of Na + , Ca2+ channels and induction of DNA methyltransferase along with inhibition of ten-eleven translocation enzymes, which can be good targets to control mucin. Mucins are strong adhesive molecules that play great roles in clinging to cells or cell to cell. Besides, they have been greatly involved in metastasis and also act as disease markers for cancers. Diagnostic markers may have exclusive roles in disease initiation and progression. Therefore, the present review explores various drugs to control and target mucin in various diseases, specifically cancers. (AU)


Pseudomyxoma Peritonei/drug therapy , Aporphines/therapeutic use , Retinoids/therapeutic use , Dexamethasone/therapeutic use , Calcium , Amiloride/therapeutic use , Methylation/drug effects , Mucins/drug effects , Naltrexone/therapeutic use
6.
Cell Cycle ; 22(8): 870-905, 2023 04.
Article En | MEDLINE | ID: mdl-36648057

Disruption of the complex network that regulates redox homeostasis often underlies resistant phenotypes, which hinder effective and long-lasting cancer eradication. In addition, the RNA methylome-dependent control of gene expression also critically affects traits of cellular resistance to anti-cancer agents. However, few investigations aimed at establishing whether the epitranscriptome-directed adaptations underlying acquired and/or innate resistance traits in cancer could be implemented through the involvement of redox-dependent or -responsive signaling pathways. This is unexpected mainly because: i) the effectiveness of many anti-cancer approaches relies on their capacity to promote oxidative stress (OS); ii) altered redox milieu and reprogramming of mitochondrial function have been acknowledged as critical mediators of the RNA methylome-mediated response to OS. Here we summarize the current state of understanding on this topic, as well as we offer new perspectives that might lead to original approaches and strategies to delay or prevent the problem of refractory cancer and tumor recurrence.


Antineoplastic Agents , Neoplasms , Oxidative Stress , RNA Processing, Post-Transcriptional , RNA , RNA/genetics , RNA/metabolism , Methylation/drug effects , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Oxidative Stress/drug effects , Neoplasms/genetics , Neoplasms/metabolism , Neoplasms/pathology , Neoplasms/therapy , Epigenesis, Genetic/drug effects , Transcriptome/drug effects , Oxidation-Reduction/drug effects , Epigenome/drug effects , Mitochondria/drug effects , Mitochondria/metabolism , Recurrence , Humans , Animals , RNA Processing, Post-Transcriptional/drug effects , Homeostasis/drug effects , Reactive Oxygen Species/metabolism
7.
J Ovarian Res ; 15(1): 126, 2022 Dec 03.
Article En | MEDLINE | ID: mdl-36463191

The survival of ovary granulosa cells (GC) is critical in the initiation and progression of polycystic ovary syndrome (PCOS) in females. Here, we found that the PCOS process is accompanied by massive GC pyroptosis resulting from Caspase-1 inflammasome activation. Administration of plumbagin, an effective compound isolated from plant medicine, can prevent the pyroptosis of GC and the onset of PCOS. Mechanistic study indicates the over-activation of the inflammasome in GC is due to the upregulation of WTAP, a key regulator of the RNA N6-methylase complex. WTAP mediates the mRNA N6-methylation of NLRP3 inflammasome component ASC and enhances ASC RNA stability, which results in the overactivation of the inflammasome in GCs from the PCOS model. Plumbagin treatment suppresses the WTAP-mediated N6-methylation of ASC mRNA and reduces the pyroptosis of GCs. This study supports the profound potential of plumbagin in PCOS treatment.


Granulosa Cells , Naphthoquinones , Polycystic Ovary Syndrome , Pyroptosis , Female , Humans , Cell Cycle Proteins/genetics , Cell Cycle Proteins/immunology , Granulosa Cells/drug effects , Granulosa Cells/immunology , Inflammasomes/genetics , Inflammasomes/immunology , Methylation/drug effects , Polycystic Ovary Syndrome/drug therapy , Polycystic Ovary Syndrome/genetics , Polycystic Ovary Syndrome/immunology , Pyroptosis/drug effects , Pyroptosis/genetics , Pyroptosis/immunology , RNA Splicing Factors/genetics , RNA Splicing Factors/immunology , RNA, Messenger , Naphthoquinones/immunology , Naphthoquinones/pharmacology , Naphthoquinones/therapeutic use
8.
Nature ; 607(7919): 593-603, 2022 07.
Article En | MEDLINE | ID: mdl-35768510

Aggressive and metastatic cancers show enhanced metabolic plasticity1, but the precise underlying mechanisms of this remain unclear. Here we show how two NOP2/Sun RNA methyltransferase 3 (NSUN3)-dependent RNA modifications-5-methylcytosine (m5C) and its derivative 5-formylcytosine (f5C) (refs.2-4)-drive the translation of mitochondrial mRNA to power metastasis. Translation of mitochondrially encoded subunits of the oxidative phosphorylation complex depends on the formation of m5C at position 34 in mitochondrial tRNAMet. m5C-deficient human oral cancer cells exhibit increased levels of glycolysis and changes in their mitochondrial function that do not affect cell viability or primary tumour growth in vivo; however, metabolic plasticity is severely impaired as mitochondrial m5C-deficient tumours do not metastasize efficiently. We discovered that CD36-dependent non-dividing, metastasis-initiating tumour cells require mitochondrial m5C to activate invasion and dissemination. Moreover, a mitochondria-driven gene signature in patients with head and neck cancer is predictive for metastasis and disease progression. Finally, we confirm that this metabolic switch that allows the metastasis of tumour cells can be pharmacologically targeted through the inhibition of mitochondrial mRNA translation in vivo. Together, our results reveal that site-specific mitochondrial RNA modifications could be therapeutic targets to combat metastasis.


5-Methylcytosine , Cytosine/analogs & derivatives , Glycolysis , Mitochondria , Neoplasm Metastasis , Oxidative Phosphorylation , RNA, Mitochondrial , 5-Methylcytosine/biosynthesis , 5-Methylcytosine/metabolism , CD36 Antigens , Cell Survival , Cytosine/metabolism , Disease Progression , Glycolysis/drug effects , Humans , Methylation/drug effects , Methyltransferases/antagonists & inhibitors , Methyltransferases/metabolism , Mitochondria/drug effects , Mitochondria/genetics , Mitochondria/metabolism , Mouth Neoplasms/genetics , Mouth Neoplasms/metabolism , Mouth Neoplasms/pathology , Neoplasm Metastasis/drug therapy , Neoplasm Metastasis/genetics , Neoplasm Metastasis/pathology , Oxidative Phosphorylation/drug effects , Protein Biosynthesis/drug effects , RNA, Mitochondrial/genetics , RNA, Mitochondrial/metabolism , RNA, Transfer, Met/genetics , RNA, Transfer, Met/metabolism
9.
Int J Mol Sci ; 23(3)2022 Jan 19.
Article En | MEDLINE | ID: mdl-35163002

Kynurenic acid (KYNA) is implicated in antiinflammatory processes in the brain through several cellular and molecular targets, among which microglia-related mechanisms are of paramount importance. In this study, we describe the effects of KYNA and one of its analogs, the brain-penetrable SZR104 (N-(2-(dimethylamino)ethyl)-3-(morpholinomethyl)-4-hydroxyquinoline-2-carboxamide), on the intracellular distribution and methylation patterns of histone H3 in immunochallenged microglia cultures. Microglia-enriched secondary cultures made from newborn rat forebrains were immunochallenged with lipopolysaccharide (LPS). The protein levels of selected inflammatory markers C-X-C motif chemokine ligand 10 (CXCL10) and C-C motif chemokine receptor 1 (CCR1), histone H3, and posttranslational modifications of histone H3 lys methylation sites (H3K9me3 and H3K36me2, marks typically associated with opposite effects on gene expression) were analyzed using quantitative fluorescent immunocytochemistry and western blots in control or LPS-treated cultures with or without KYNA or SZR104. KYNA and SZR104 reduced levels of the inflammatory marker proteins CXCL10 and CCR1 after LPS-treatment. Moreover, KYNA and SZR104 favorably affected histone methylation patterns as H3K9me3 and H3K36me2 immunoreactivities, and histone H3 protein levels returned toward control values after LPS treatment. The cytoplasmic translocation of H3K9me3 from the nucleus indicated inflammatory distress, a process that could be inhibited by KYNA and SZR104. Thus, KYNA signaling and metabolism, and especially brain-penetrable KYNA analogs such as SZR104, could be key targets in the pathway that connects chromatin structure and epigenetic mechanisms with functional consequences that affect neuroinflammation and perhaps neurodegeneration.


Amides/pharmacology , Anti-Inflammatory Agents/pharmacology , Histones/metabolism , Kynurenic Acid/pharmacology , Lipopolysaccharides/adverse effects , Microglia/cytology , Amides/chemistry , Animals , Animals, Newborn , Anti-Inflammatory Agents/chemistry , Cells, Cultured , Chemokine CXCL10/metabolism , Disease Models, Animal , Epigenesis, Genetic/drug effects , Female , Kynurenic Acid/analogs & derivatives , Male , Methylation/drug effects , Microglia/drug effects , Microglia/metabolism , Pregnancy , Rats , Receptors, CCR1/metabolism
10.
Cells ; 11(2)2022 01 15.
Article En | MEDLINE | ID: mdl-35053407

Type 2 diabetes is characterized by chronic hyperglycemia associated with impaired insulin action and secretion. Although the heritability of type 2 diabetes is high, the environment, including blood components, could play a major role in the development of the disease. Amongst environmental effects, epitranscriptomic modifications have been recently shown to affect gene expression and glucose homeostasis. The epitranscriptome is characterized by reversible chemical changes in RNA, with one of the most prevalent being the m6A methylation of RNA. Since pancreatic ß cells fine tune glucose levels and play a major role in type 2 diabetes physiopathology, we hypothesized that the environment, through variations in blood glucose or blood free fatty acid concentrations, could induce changes in m6A methylation of RNAs in pancreatic ß cells. Here we observe a significant decrease in m6A methylation upon high glucose concentration, both in mice and human islets, associated with altered expression levels of m6A demethylases. In addition, the use of siRNA and/or specific inhibitors against selected m6A enzymes demonstrate that these enzymes modulate the expression of genes involved in pancreatic ß-cell identity and glucose-stimulated insulin secretion. Our data suggest that environmental variations, such as glucose, control m6A methylation in pancreatic ß cells, playing a key role in the control of gene expression and pancreatic ß-cell functions. Our results highlight novel causes and new mechanisms potentially involved in type 2 diabetes physiopathology and may contribute to a better understanding of the etiology of this disease.


Adenosine/analogs & derivatives , Glucose/metabolism , Islets of Langerhans/metabolism , RNA/metabolism , Adenosine/metabolism , AlkB Homolog 5, RNA Demethylase/genetics , AlkB Homolog 5, RNA Demethylase/metabolism , Alpha-Ketoglutarate-Dependent Dioxygenase FTO/metabolism , Animals , Cell Line , Down-Regulation/drug effects , Glucose/pharmacology , Insulin Secretion/drug effects , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/metabolism , Islets of Langerhans/drug effects , Methylation/drug effects , Mice , Mice, Inbred C57BL , Palmitates/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism
11.
Clin Transl Med ; 12(1): e686, 2022 01.
Article En | MEDLINE | ID: mdl-35090076

BACKGROUND: Protein arginine methylation has emerged a pivotal role in cancer progression. However, the role of protein arginine methyltransferase 3 (PRMT3) in hepatocellular carcinoma (HCC) remains unknown. METHODS: The expression pattern of PRMT3 in HCC was analysed using quantitative real-time-polymerase chain reaction (qRT-PCR), Western blotting and immunohistochemistry assays. Loss- and gain-of-function experiments were carried out to determine the oncogenic role of PRMT3 in HCC. Glucose consumption and lactate production assays, seahorse bioscience, mass spectrometry, co-immunoprecipitation, metabonomic analysis and site-specific mutation experiments were used to explore the underlying molecular mechanisms. Furthermore, a xenograft mouse model was established to investigate the effects of PRMT3 and its inhibitor, SGC707, treatment on tumour growth in vivo. RESULTS: The expression of PRMT3 was significantly upregulated in HCC, with high expression of which correlated with poor prognosis. PRMT3 knockdown led to the decrease in proliferation, glycolysis of HCC cells and tumour growth, whilst its overexpression showed opposite results. The catalytic activity of PRMT3 was important in mediating these biological processes. Mechanistically, our data showed that PRMT3 interacted with and mediated asymmetric dimethylarginine (ADMA) modification of lactate dehydrogenase A (LDHA) at arginine 112 (R112). Compared with LDHA-wild-type (LDHA-WT) cells, LDHA-R112K-mutant-expressing HCC cells exhibited a decrease in lactate dehydrogenase (LDH) activity, HCC cell glycolysis and proliferation. Furthermore, the administration of SGC707, a selective inhibitor of PRMT3, disrupted the PRMT3-mediated LDHA methylation and abolished PRMT3-induced HCC glycolysis and tumour growth. CONCLUSIONS: Our results suggested a novel oncogenic role of PRMT3 in HCC, and it could be a promising therapeutic target for HCC by linking post-translational modification and cancer metabolism.


Carcinoma, Hepatocellular/drug therapy , Glycolysis/drug effects , L-Lactate Dehydrogenase/pharmacology , Protein-Arginine N-Methyltransferases/pharmacology , Animals , Cell Line, Tumor/drug effects , Cell Line, Tumor/metabolism , Cell Proliferation/drug effects , China , Disease Models, Animal , Histology/instrumentation , Histology/trends , Humans , L-Lactate Dehydrogenase/metabolism , Liver Neoplasms/drug therapy , Methylation/drug effects , Mice , Protein-Arginine N-Methyltransferases/metabolism
12.
Plant Physiol ; 188(1): 460-476, 2022 01 20.
Article En | MEDLINE | ID: mdl-34730827

Lateral branches such as shoot and panicle are determining factors and target traits for rice (Oryza sativa L.) yield improvement. Cytokinin promotes rice lateral branching; however, the mechanism underlying the fine-tuning of cytokinin homeostasis in rice branching remains largely unknown. Here, we report the map-based cloning of RICE LATERAL BRANCH (RLB) encoding a nuclear-localized, KNOX-type homeobox protein from a rice cytokinin-deficient mutant showing more tillers, sparser panicles, defected floret morphology as well as attenuated shoot regeneration from callus. RLB directly binds to the promoter and represses the transcription of OsCKX4, a cytokinin oxidase gene with high abundance in panicle branch meristem. OsCKX4 over-expression lines phenocopied rlb, which showed upregulated OsCKX4 levels. Meanwhile, RLB physically binds to Polycomb repressive complex 2 (PRC2) components OsEMF2b and co-localized with H3K27me3, a suppressing histone modification mediated by PRC2, in the OsCKX4 promoter. We proposed that RLB recruits PRC2 to the OsCKX4 promoter to epigenetically repress its transcription, which suppresses the catabolism of cytokinin, thereby promoting rice lateral branching. Moreover, antisense inhibition of OsCKX4 under the LOG promoter successfully increased panicle size and spikelet number per plant without affecting other major agronomic traits. This study provides insight into cytokinin homeostasis, lateral branching in plants, and also promising target genes for rice genetic improvement.


Meristem/genetics , Meristem/metabolism , Oryza/growth & development , Oryza/genetics , Oryza/metabolism , Plant Growth Regulators/genetics , Plant Growth Regulators/metabolism , Crops, Agricultural/genetics , Crops, Agricultural/growth & development , Crops, Agricultural/metabolism , Gene Expression Regulation, Plant , Genes, Plant , Genetic Variation , Genotype , Methylation/drug effects , Plants, Genetically Modified
13.
FEBS J ; 289(5): 1315-1328, 2022 03.
Article En | MEDLINE | ID: mdl-33969633

Since the discovery of recurrent mutations in histone H3 variants in paediatric brain tumours, so-called 'oncohistones' have been identified in various cancers. While their mechanism of action remains under active investigation, several studies have shed light on how they promote genome-wide epigenetic perturbations. These findings converge on altered post-translational modifications on two key lysine (K) residues of the H3 tail, K27 and K36, which regulate several cellular processes, including those linked to cell differentiation during development. We will review how these oncohistones affect the methylation of cognate residues, but also disrupt the distribution of opposing chromatin marks, creating genome-wide epigenetic changes which participate in the oncogenic process. Ultimately, tumorigenesis is promoted through the maintenance of a progenitor state at the expense of differentiation in defined cellular and developmental contexts. As these epigenetic disruptions are reversible, improved understanding of oncohistone pathogenicity can result in needed alternative therapies.


Chromatin/metabolism , Epigenesis, Genetic , Histones/genetics , Neoplasms/genetics , Oncogenes , Protein Processing, Post-Translational , Antineoplastic Agents/therapeutic use , Carcinogenesis/genetics , Carcinogenesis/metabolism , Carcinogenesis/pathology , Cell Differentiation , Chromatin/chemistry , Chromatin/drug effects , Complementary Therapies , Gene Expression Regulation, Neoplastic , Histones/metabolism , Humans , Methylation/drug effects , Molecular Targeted Therapy , Mutation , Neoplasms/drug therapy , Neoplasms/metabolism , Neoplasms/pathology , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Polycomb-Group Proteins/genetics , Polycomb-Group Proteins/metabolism
14.
Chem Biodivers ; 19(1): e202100681, 2022 Jan.
Article En | MEDLINE | ID: mdl-34817123

This study aims to establish the isolation and purification method of polysaccharides from medicinal residue of Panax notoginseng (PPN). The structure and protective effect of PPN on myelosuppression mice were investigated. One neutral polysaccharide (NPPN) and five acidic polysaccharides (APPN I, APPN II-A, APPN II-B, APPN III-A, and APPN III-B) were obtained. The results confirmed that NPPN, APPN I and APPN II-A are glycan with 1, 4 main chains. APPN III-A is a glycan. APPN II-B and APPN III-B are homogalacturonan pectin with 1, 4 main chains. This study demonstrated that NPPN played a bone marrow protective role in myelosuppression mice induced by cyclophosphamide. NPPN could relieve cell cycle arrest, reduce the apoptosis rate of marrow cells, and improve granulocyte-macrophage colony-stimulating (GM-CSF), thermoplastic polyolefin (TPO) and erythropoietin (EPO) serum level, which contributes to promoting the proliferation of hematopoietic cells.


Bone Marrow Cells/drug effects , Cyclophosphamide/pharmacology , Panax notoginseng/metabolism , Polysaccharides/chemistry , Animals , Apoptosis/drug effects , Bone Marrow Cells/cytology , Bone Marrow Cells/metabolism , Cell Cycle Checkpoints/drug effects , Cell Proliferation/drug effects , Erythropoietin/blood , Female , Granulocyte-Macrophage Colony-Stimulating Factor/blood , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/metabolism , Methylation/drug effects , Mice , Polysaccharides/isolation & purification , Polysaccharides/pharmacology
15.
Chem Biol Interact ; 351: 109759, 2022 Jan 05.
Article En | MEDLINE | ID: mdl-34826399

Hypoxia/oxygen-sensing signally is closely associated with many tumor progressions, including osteosarcoma (OS). Previous research principally focused on the function of hypoxia-inducible factor (HIF)-1α and HIF-2α as the major hypoxia-associated transcription factors in OS, however, the role of HIF-3α has not been investigated. Our study found that HIF-3α was upregulated in OS tissues and cell lines. HIF-3α overexpression facilitated cell proliferation and invasion, and inhibited apoptosis, whereas HIF-3α knockdown showed the opposite results. Chromatin immunoprecipitation analysis revealed that lysine demethylase 3A (KDM3A) expression was transcriptionally activated by HIF-3α under hypoxia, and KDM3A occupied the SRY-box transcription factor 9 (SOX9) gene promoter region through H3 lysine 9 dimethylation (H3K9me2). Additionally, rescue results revealed that KDM3A or SOX9 overexpression reversed the effects of HIF-3α silence on cell functions. The Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathway inhibitor cucurbitacin I suppressed the promotive effects of HIF-3α overexpression on cell proliferation, invasion and TAK2/STAT3 pathway. Finally, OS cell line MG-63 transfected with HIF-3α short hairpin RNA (HIF-3α shRNA) were subcutaneously injected into nude mice, and the results found that HIF-3α knockdown significantly inhibited the xenograft tumor growth of OS in vivo. In conclusion, this study reveals that HIF-3α promotes OS progression in vitro and in vivo by activating KDM3A-mediated SOX9 promoter demethylation, which may provide a potential therapeutic mechanism for OS.


Apoptosis Regulatory Proteins/metabolism , Bone Neoplasms/physiopathology , Jumonji Domain-Containing Histone Demethylases/metabolism , Osteosarcoma/physiopathology , Repressor Proteins/metabolism , SOX9 Transcription Factor/metabolism , Animals , Apoptosis/physiology , Cell Proliferation/physiology , Female , Humans , Male , Methylation/drug effects , Mice, Inbred BALB C , Signal Transduction/physiology
16.
Cancer Genomics Proteomics ; 19(1): 12-18, 2022.
Article En | MEDLINE | ID: mdl-34949655

BACKGROUND/AIM: Methionine addiction is a fundamental and general hallmark of cancer, termed the Hoffman effect. Methionine addiction is due to excessive use of and dependence on methionine by cancer cells. In the present report, we correlated the extent of methionine addiction and degree of malignancy with the amount and stability of methylated histone H3 lysine marks. MATERIALS AND METHODS: We established low- and high-malignancy variants from a parental human pancreatic-cancer cell line and compared their sensitivity to methionine restriction and histone H3 lysine methylation status. RESULTS: A low-malignancy, low-methionine-addiction revertant of the parental pancreatic-cancer cell line had less methylated H3K9me3 and was less sensitive to methionine restriction effected by recombinant methioninase (rMETase) than the parental cell line. A high-malignancy variant of the pancreatic cancer cell line had increased methylated H3K9me3 and was more sensitive to methionine restriction by rMETase with regard to inhibition of proliferation and to instability of histone H3 lysine methylation than the parental cell line. Orthotopic malignancy in nude mice was reduced in the low-methionine-addiction revertant and greater in the high-malignancy variant than in the parental cell line. CONCLUSION: The present study indicates that the degree of malignancy is linked to the extent of methionine addiction and the level and instability of trimethylation of histone H3, suggesting these phenomena are linked as a fundamental basis of oncogenic transformation.


Cell Transformation, Neoplastic/genetics , Histones/metabolism , Methionine/metabolism , Pancreatic Neoplasms/genetics , Animals , Carbon-Sulfur Lyases/pharmacology , Carbon-Sulfur Lyases/therapeutic use , Cell Line, Tumor , Cell Transformation, Neoplastic/drug effects , Histone Code/drug effects , Humans , Lysine/metabolism , Methylation/drug effects , Mice , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/pathology , Recombinant Proteins/pharmacology , Recombinant Proteins/therapeutic use , Tumor Burden , Xenograft Model Antitumor Assays
17.
Bioorg Med Chem ; 53: 116524, 2022 01 01.
Article En | MEDLINE | ID: mdl-34847495

Cancer is a common malignant disease with complex signaling networks, which means it is unmanageable to cancer therapy by using single classical targeted drug. Recently, dual- or multitarget drugs have emerged as a promising option for cancer therapies. Although many multifunctional compounds targeting HDAC have been validated, as far as we know, there is no molecule targeting GLP and HDAC synchronously. In the present work, we designed and synthesized a series of quinazoline-based hydroxamic acid derivatives as dual GLP and HDAC inhibitors. These hybrid compounds showed potent enzymatic inhibitory activities against GLP and HDAC1/6 with IC50 values in the nanomolar range of less than 190 nM. Furthermore, most of our compounds displayed significant broad spectrum cytotoxic activities apart from D3 and D8 against all the tested cancer cells with IC50 values less than 50 µM. D1, D6 and D7 showed more potent cytotoxic activities than D2, D4 and D5 in those cancer cells. Especially, compound D7 showed potent inhibitory potency activity against both GLP and HDAC1/6 with IC50 values of 1.3, 89, 13 nM. Besides, D7 exhibited the most potent antiproliferative activity against all the tested cancer cells. Further evaluations indicated that D7 could inhibit the methylation and deacetylation of H3K9 on protein level. Moreover, D7 could induce cancer cell apoptosis, G0/G1 cell cycle arrest, and partly block migration and invasion. All these thorough evaluations warranted D7 as a promising lead compound worth further optimization and development for cancer therapy.


Antineoplastic Agents/pharmacology , Histone Deacetylase Inhibitors/pharmacology , Histone Deacetylases/metabolism , Histones/antagonists & inhibitors , Hydroxamic Acids/pharmacology , Quinazolines/pharmacology , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Cell Cycle Checkpoints/drug effects , Cell Movement/drug effects , Cell Proliferation/drug effects , Dose-Response Relationship, Drug , Drug Screening Assays, Antitumor , Histone Deacetylase Inhibitors/chemical synthesis , Histone Deacetylase Inhibitors/chemistry , Histones/metabolism , Humans , Hydroxamic Acids/chemistry , Methylation/drug effects , Molecular Structure , Quinazolines/chemistry , Structure-Activity Relationship , Tumor Cells, Cultured
18.
JCI Insight ; 6(23)2021 12 08.
Article En | MEDLINE | ID: mdl-34877932

Tristetraprolin (TTP), an important immunosuppressive protein regulating mRNA decay through recognition of the AU-rich elements (AREs) within the 3'-UTRs of mRNAs, participates in the pathogenesis of liver diseases. However, whether TTP regulates mRNA stability through other mechanisms remains poorly understood. Here, we report that TTP was upregulated in acute liver failure (ALF), resulting in decreased mRNA stabilities of CCL2 and CCL5 through promotion of N6-methyladenosine (m6A) mRNA methylation. Overexpression of TTP could markedly ameliorate hepatic injury in vivo. TTP regulated the mRNA stabilization of CCL2 and CCL5. Interestingly, increased m6A methylation in CCL2 and CCL5 mRNAs promoted TTP-mediated RNA destabilization. Moreover, induction of TTP upregulated expression levels of WT1 associated protein, methyltransferase like 14, and YT521-B homology N6-methyladenosine RNA binding protein 2, which encode enzymes regulating m6A methylation, resulting in a global increase of m6A methylation and amelioration of liver injury due to enhanced degradation of CCL2 and CCL5. These findings suggest a potentially novel mechanism by which TTP modulates mRNA stabilities of CCL2 and CCL5 through m6A RNA methylation, which is involved in the pathogenesis of ALF.


Chemokine CCL2/metabolism , Chemokine CCL5/metabolism , Liver Failure, Acute/drug therapy , Methylation/drug effects , RNA-Binding Proteins/drug effects , Tristetraprolin/therapeutic use , Animals , Humans , Mice , Tristetraprolin/pharmacology
19.
Cells ; 10(12)2021 12 03.
Article En | MEDLINE | ID: mdl-34943918

Experiments on Vicia faba root meristem cells exposed to 150 µM cadmium chloride (CdCl2) were undertaken to analyse epigenetic changes, mainly with respect to DNA replication stress. Histone modifications examined by means of immunofluorescence labeling included: (1) acetylation of histone H3 on lysine 56 (H3K56Ac), involved in transcription, S phase, and response to DNA damage during DNA biosynthesis; (2) dimethylation of histone H3 on lysine 79 (H3K79Me2), correlated with the replication initiation; (3) phosphorylation of histone H3 on threonine 45 (H3T45Ph), engaged in DNA synthesis and apoptosis. Moreover, immunostaining using specific antibodies against 5-MetC-modified DNA was used to determine the level of DNA methylation. A significant decrease in the level of H3K79Me2, noted in all phases of the CdCl2-treated interphase cell nuclei, was found to correspond with: (1) an increase in the mean number of intranuclear foci of H3K56Ac histones (observed mainly in S-phase), (2) a plethora of nuclear and nucleolar labeling patterns (combined with a general decrease in H3T45Ph), and (3) a decrease in DNA methylation. All these changes correlate well with a general viewpoint that DNA modifications and post-translational histone modifications play an important role in gene expression and plant development under cadmium-induced stress conditions.


Cadmium/toxicity , DNA Replication/genetics , Epigenesis, Genetic , Meristem/cytology , Meristem/genetics , Stress, Physiological/genetics , Vicia faba/genetics , 5-Methylcytosine/metabolism , Acetylation/drug effects , Cell Cycle/drug effects , Cell Cycle/genetics , Chromatin/metabolism , DNA Replication/drug effects , DNA, Plant/metabolism , Epigenesis, Genetic/drug effects , Histones/metabolism , Lysine/metabolism , Meristem/drug effects , Methylation/drug effects , Phosphorylation/drug effects , Stress, Physiological/drug effects , Vicia faba/cytology , Vicia faba/drug effects
20.
Front Immunol ; 12: 769204, 2021.
Article En | MEDLINE | ID: mdl-34880865

Background: The n6-methyladenosine (m6A) modification is present widely in mRNAs and long non-coding RNAs (lncRNAs), and is related to the occurrence and development of certain diseases. However, the role of m6A methylation in Clostridium perfringens type C infectious diarrhea remains unclear. Methods: Here, we treated intestinal porcine jejunum epithelial cells (IPEC-J2 cells) with Clostridium perfringens beta2 (CPB2) toxin to construct an in vitro model of Clostridium perfringens type C (C. perfringens type C) infectious diarrhea, and then used methylated RNA immunoprecipitation sequencing (MeRIP-seq) and RNA sequencing (RNA-seq) to identify the methylation profiles of mRNAs and lncRNAs in IPEC-J2 cells. Results: We identified 6,413 peaks, representing 5,825 m6A-modified mRNAs and 433 modified lncRNAs, of which 4,356 m6A modified mRNAs and 221 m6A modified lncRNAs were significantly differential expressed between the control group and CPB2 group. The motif GGACU was enriched significantly in both the control group and the CPB2 group. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) annotation analysis showed that the differentially methylated modified mRNAs were mainly enriched in Hippo signaling pathway and Wnt signaling pathway. In addition, the target genes of the differentially m6A modified lncRNAs were related to defense response to virus and immune response. For example, ENSSSCG00000042575, ENSSSCG00000048701 and ENSSSCG00000048785 might regulate the defense response to virus, immune and inflammatory response to resist the harmful effects of viruses on cells. Conclusion: In summary, this study established the m6A transcription profile of mRNAs and lncRNAs in IPEC-J2 cells treated by CPB2 toxin. Further analysis showed that m6A-modified RNAs were related to defense against viruses and immune response after CPB2 toxin treatment of the cells. Threem6A-modified lncRNAs, ENSSSCG00000042575, ENSSSCG00000048785 and ENSSSCG00000048701, were most likely to play a key role in CPB2 toxin-treated IPEC-J2 cells. The results provide a theoretical basis for further research on the role of m6A modification in piglet diarrhea.


Adenosine/analogs & derivatives , Bacterial Toxins/pharmacology , Epithelial Cells/drug effects , RNA, Long Noncoding/genetics , RNA, Messenger/genetics , Adenosine/metabolism , Animals , Cell Line , Clostridium Infections/genetics , Clostridium Infections/metabolism , Clostridium Infections/microbiology , Clostridium perfringens/metabolism , Clostridium perfringens/physiology , Epithelial Cells/metabolism , Gene Expression Regulation/drug effects , Gene Ontology , Intestinal Mucosa/cytology , Methylation/drug effects , RNA, Long Noncoding/metabolism , RNA, Messenger/metabolism , RNA-Seq/methods , Reverse Transcriptase Polymerase Chain Reaction/methods , Signal Transduction/drug effects , Signal Transduction/genetics , Swine , Transcriptome/genetics
...